hdac1

(2E)-N-(4-methoxyphenyl)-3-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-enamide is a compound used as a molecular structural unit.

HDAC1/6-IN-1 is a potent multi-target inhibitor of GLP (IC50: 1.3 nM), HDAC6 (IC50: 13 nM) and HDAC1 (IC50: 89 nM). HDAC1/6-IN-1 inhibits the methylation and deacetylation of H3K9 at the protein level. HDAC1/6-IN-1 can block the cell cycle of cancer cells in G0/G1 phase, induce apoptosis and prevent cancer cell migration and invasion.

HDAC1 MAO-B-IN-1 has the potential to be used in the Alzheimer’s disease research. HDAC1 MAO-B-IN-1 is a potent and selective inhibitor of HDAC1 MAO-B that can cross the blood-brain barrier. The IC50 values of HDAC1 MAO-B-IN-1 for HDAC1 and MAO-B are 21.4 nM and 99.0 nM, respectively [1].

HDAC1 2 and CDK2-IN-1 (compound 14d) are potent inhibitors of HDAC1, HDAC2, and CDK2 with IC50 values of 70.7, 23.1, and 0.80 μM, respectively. HDAC1 2 and CDK2-IN-1 can block the cell cycle and induce apoptosis, demonstrating good anti-tumor effects in vivo.

VEGFR2 HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC. It arrests the cell cycle at the S and G2 phases and induces apoptosis in HeLa cells, demonstrating an anti-angiogenic effect [1].

HDAC1 CDK7-IN-1 (compound 8e) is a dual inhibitor of CDK7 and HDAC1, with IC50 values of 893 nM and 248 nM, respectively. It suppresses the proliferation of cancer cell lines such as MDA-MB-231, MCF-7, A549, and HCT-116, induces cell cycle arrest and apoptosis in HCT-116 cells, and impedes their migration [1].

mTOR/HDAC-IN-1 HCl is a potent dual inhibitor of mTOR and HDAC with potential anti-inflammatory, anti-proliferative, autophagy and apoptosis-inducing effects for cancer research.

mTOR HDAC-IN-1 (Compound 50) is a dual inhibitor of mTOR and HDAC, with IC50 values of 0.49 nM and 0.91 nM, respectively, holding potential as an anti-cancer agent [1].

IDO1 and HDAC1 Inhibitor is a dual IDO1 and HDAC1 inhibitor (IC50s: 69.0 nM and 66.5 nM).

HDAC1/2-IN-3 is an inhibitor of both HDAC1 and HDAC2, demonstrating IC50 values of 0-5 nM and 5-10 nM, respectively.

HDAC1-IN-3 is a potent inhibitor of Pf HDAC1, exhibiting a significant in vivo killing effect on all life cycles of the parasite and displaying antimalarial activity in both wild-type and multidrug-resistant strains of the parasite.

HDAC1-IN-5, a potent inhibitor of HDAC1 with an IC50 value of 15 nM, also exhibits inhibitory activity towards HDAC6 with an IC50 value of 20 nM. In cancer cells, HDAC1-IN-5 enhances the acetylation of both histone H3 and α-tubulin, leading to the activation of caspase 3 and induction of apoptosis. Additionally, HDAC1-IN-5 binds with DNA, causing chromatin damage. Furthermore, it demonstrated strong inhibitory activity against tumor growth in xenograft mice. [1]

HDAC1-IN-4 is a potent inhibitor of Plasmodium falciparum HDAC1 (PfHDAC1) with low cytotoxicity and antimalarial effects (IC50<5 nM).

Compound A5b, also known as JMJD3/HDAC-IN-1, is a dual inhibitor that targets both JMJD3 (Jumonji domain-containing protein demethylase 3) and HADC1 (histone deacetylase, IC50 = 16 nM). It induces hypermethylation of histone H3K27 and hyperacetylation of H3K9, while also promoting apoptosis through the cleavage of caspase-7 and PARP. This compound has demonstrated the ability to effectively inhibit cancer cell cloning, migration, and invasion [1].

HDAC CD13-IN-1 (Compound 12) is an inhibitor of both HDAC and CD13, with IC50 values of 0.34 μM for hCD13, 0.53 μM for porcine CD13, and 0.03, 0.06, and 0.02 μM for HDAC1, HDAC2, and HDAC3, respectively. This compound effectively suppresses proliferation and induces apoptosis in MV4-11, K562, Jeko-1, and HL60 cancer cells, with IC50 ranges of 0.25-2.04 μM, and demonstrates capabilities in hindering metastasis and invasion [1].

HDAC/BET-IN-1 is a chemical compound exhibiting submicromolar inhibitory activity against HDAC1 and HDAC6, with IC50 values of 0.163 μM and 0.067 μM, respectively, and against BRD4, with a Ki of 0.076 μM. Additionally, it possesses potent antileukemia activity.

HDAC/Top-IN-1 is a broad-spectrum, orally active dual HDAC/Top inhibitor that acts on HDAC1 (IC50: 0.036 μM), HDAC2 (IC50: 0.14 μM), HDAC3 (IC50: 0.059 μM), HDAC6 (IC50: 0.089 μM) and HDAC8 ( IC50: 9.8 μM). HDAC/Top-IN-1 was able to block HEL cells in S-phase and effectively induce apoptosis.

SHP2/HDAC-IN-1, a dual allosteric inhibitor targeting SHP2 and HDAC, exhibits potent inhibitory effects with IC 50 values of 20.4 nM (SHP2) and 25.3 nM (HDAC1), respectively. This compound activates T cells, enhances antigen presentation, and promotes cytokine secretion, facilitating efficient antitumor immunity. It holds potential for cancer immunotherapy research.

Snail HDAC-IN-1 is a Snail HDAC inhibitor with antimicrobial and anticancer activity, known to reduce Snail protein expression and induce apoptosis, making it useful for the study of solid tumors.

NMDAR HDAC-IN-1 (Compound 9d) is a potent dual inhibitor of N-methyl-D-aspartate receptors (NMDARs) and histone deacetylases (HDACs), with a high affinity for NMDARs (Ki = 0.59 μM) and significant inhibitory effects on various HDAC isoforms, including HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 with IC50 values of 2.67 μM, 8.00 μM, 2.21 μM, 0.18 μM, and 0.62 μM, respectively; additionally, it efficiently crosses the blood-brain barrier [1].

A2AAR HDAC-IN-1 (compound 14c) is an orally active, balanced dual inhibitor of A2AAR (Ki: 163.5 nM) and HDAC1 (IC50: 145.3 nM).

PARP HDAC-IN-1 is a selective PARP and HDAC inhibitor with potential anticancer activity, inhibits PARP1, PARP2 and HDAC1, and may be used in the study of pancreatic cancer.

PI3K HDAC-IN-1 is a potent dual inhibitor of PI3K and HDAC, with IC50 values of 8.1 nM and 1.4 nM, respectively.

Top/HDAC-IN-1 is a dual topoisomerase (Top)/HDAC inhibitor that acts on HDAC1 (IC50: 18 nM), HDAC2 (IC50: 230 nM), HDAC3 (IC50: 790 nM), HDAC6 (IC50: 87 nM) and HDAC8 (IC50: 5250 nM). Top/HDAC-IN-1 exhibited potent antitumor effects on HCT116 cells (IC50: 180 nM), blocked the cell cycle of HCT116 cells in G2 phase, and effectively induced apoptosis.

HDAC ligand-1 is a synthetic precursor utilized in the production of PROTAC-based HDAC degraders [1].

HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4. This compound not only inhibits cell proliferation but also induces apoptosis in MDA-MB-231 cells and demonstrates in vivo anticancer efficacy [1].

PARP-1 HDAC-IN-1 is an effective dual inhibitor of PARP-1 and HDAC6, with IC50 values of 68.90 nM and 510 nM, respectively. PARP-1 HDAC-IN-1 exhibits anti-cancer, anti-migration, and anti-angiogenesis activities.

MAO A HDAC-IN-1 is an effective dual inhibitor of monoamine oxidase A (MAO A) and HDAC, suitable for glioma research.

PDE5/HDAC-IN-1 is a potent inhibitor of phosphodiesterase 5 (PDE5) and HDAC, with IC50 values of 46.3 nM and 14.5 nM, respectively.

CYP51/HDAC-IN-1 is an orally active, potent, dual CYP51/HDAC inhibitor that inhibits important virulence factors and down-regulates the expression of associated drug resistance genes.CYP51/HDAC-IN-1 has shown effective therapeutic effects in both Candidiasis tropicalis and Cryptococcal meningitis.

PIM-1 HDAC-IN-1 (compound 4d) is a potent PIM-1 inhibitor with an IC50 of 343.87 nM, and it exhibits strong inhibitory activity and selectivity against HDAC 1 and HDAC 6, with IC50 values of 63.65 and 62.39 nM, respectively. Additionally, it induces apoptosis and causes G2 M phase cell cycle arrest in MCF-7 cell lines, specifically inducing pre-G1 apoptosis [1].

G4/HDAC-IN-1, a dual-targeting compound for G4 and HDAC, shows inhibition of intracellular HDAC activity, with an IC50 value of 1.1 μM, and promotes G4 formation. It effectively inhibits proliferation and tumor growth in a TNBC xenograft model, presenting potential for cancer research applications.

CDK/HDAC-IN-1 exhibits potent inhibitory activity towards CDK2/4/6 and HDAC6, with IC50 values of 60.9 ± 2.9 nM, 276 ± 22.3 nM, 27.2 ± 4.2 nM, and 128.6 ± 0.4 nM, respectively.

COX-2-IN-23 (compound A10) is a potent inhibitor of AChE (IC50: 0.12 nM) and HDAC (IC50: 0.23 nM), exhibiting antioxidant and metal-chelating properties, which can be used to study Alzheimer's disease.

Tubulin HDAC-IN-1 is a dual inhibitor of tubulin and HDAC8, interacting with tubulin via CH π interactions and with HDAC8 through hydrogen bonds. It effectively inhibits tubulin polymerization and selectively targets HDAC8 with an IC50 of 150 nM. Additionally, Tubulin HDAC-IN-1 demonstrates cytotoxicity against various human cancer cells, induces cell cycle arrest in the G2 M phase, and triggers cell apoptosis, making it valuable for studying hematologic and solid tumors, including neuroblastoma and leukemia [1].

Tacedinaline (CI994) is a selective class I HDAC inhibitor with potential antineoplastic activity.

Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.

Vorinostat (SAHA) is a pan-histone deacetylase (HDAC) inhibitor (IC50=10 nM) with inhibitory activity against HDAC1/2/3/6/7/11. Vorinostat has antitumor activity, induces cell differentiation, blocks the cell cycle and induces apoptosis.

Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that inhibits HDAC1 activity, induces HDAC2 degradation, and is orally active. Valproic Acid can be used in epilepsy and bipolar disorder research.

Parthenolide ((-)-Parthenolide) is a natural sesquiterpene lactone that is an NF-κB inhibitor and also specifically inhibits HDAC1 protein, but is inactive against other class I II HDACs. Parthenolide has anti-inflammatory, anti-tumor, and anti-viral activities.

Exifone (NSC-680919) is a mixed, nonessential activator of HDAC1 that is capable of binding to both free and substrate-bound enzyme, resulting in an increased relative maximal rate of HDAC1-catalyzed deacetylation.

HDAC-IN-7 (HBI-8000) (Chidamide impurity) is an impurity of Chidamide, a potent and orally bioavailable inhibitor of HDAC enzymes class I (HDAC1 2 3) and class IIb [HDAC10].

HDAC-IN-52, a pyridine-containing HDAC inhibitor, effectively inhibits HDAC1, HDAC2, HDAC3, and HDAC10 with IC50 values of 0.189, 0.227, 0.440, and 0.446 μM, respectively. HDAC-IN-52 can be used in cancer research.

HDAC-IN-57 is an orally active pan-inhibitor of histone deacetylase (HDAC), inhibiting HDAC1, HDAC2, HDAC6, and HDAC8 with IC50 values of 2.07 nM, 4.71 nM, 2.4 nM, and 107 nM, respectively. HDAC-IN-57 inhibits LSD1 with an IC50 value of 1.34 μΜ. HDAC-IN-57 has anti-tumor activity and can induce apoptosis.

BRD4097, a negative control in the HDAC1/2/3/8 assay, is a selective histone deacetylase (HDAC3) inhibitor that can be used to protect b-cells and improve insulin resistance, help promote cognitive function and enhance learning and memory formation.

Givinostat hydrochloride (ITF2357 hydrochloride) is an inhibitor of HDAC with IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat hydrochloride exhibits anti-inflammatory, anti-angiogenic, and antineoplastic activities.